Idarubicin Clinical Trials

12 actively recruiting trials across 4 locations

▼ -1 trial since May 2026

Also known as: 4-DMDR, 4-Demethoxydaunomycin, 4-Demethoxydaunorubicin, 4-demethoxydaunorubicin, IDA +1 more

Pipeline

Phase 1: 2Phase 2: 5Phase 1/2: 3Phase 2/3: 1

Top Sponsors

M.D. Anderson Cancer Center5
Fred Hutchinson Cancer Center3
University Hospital, Angers1
OHSU Knight Cancer Institute1
Kura Oncology, Inc.1

Indications

Cancer12
Acute Myeloid Leukemia7
Refractory Acute Myeloid Leukemia5
Recurrent Acute Myeloid Leukemia5
High-risk Myelodysplastic Syndrome4

Houston, Texas5 trials

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M D Anderson Cancer Center

Phase 2

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M D Anderson Cancer Center

Phase 2

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 2

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 1/2

Seattle, Washington3 trials

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Other2 trials

MRD-positive AML Clinical Study

N/A

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Phase 2/3

Gilbert, Arizona1 trial

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Banner MD Anderson Cancer Center

Phase 1

Portland, Oregon1 trial

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.